Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 18;12(3):489-497.
doi: 10.1093/nop/npae114. eCollection 2025 Jun.

Children with medulloblastoma treated with modified ACNS0821 temozolomide, irinotecan, and bevacizumab: The Seattle Children's Hospital experience

Rebecca Ronsley  1   2   3 , Miranda C Bradford  4 , Erin E Crotty  1   2   3 , Nicholas A Vitanza  1   2   3 , Daniel V Runco  1   2   3 , Jeffrey Stevens  3 , Corinne Hoeppner  3 , Susan L Holtzclaw  3 , Amy R Wein  3 , Amy Lee  5 , Bonnie L Cole  6 , Ralph Ermoian  7 , Sarah E S Leary  1   2   3
Affiliations

Children with medulloblastoma treated with modified ACNS0821 temozolomide, irinotecan, and bevacizumab: The Seattle Children's Hospital experience

Rebecca Ronsley et al. Neurooncol Pract. .

Abstract

Background: Effective therapy for medulloblastoma at the time of relapse is limited. The objective of this study is to review outcomes from the Seattle Children's Hospital (SCH) institutional standard therapy for relapsed medulloblastoma, modified from the published ACNS0821 regimen.

Methods: Retrospective review of patients treated for relapsed medulloblastoma from 2012-2024 treated with modified ACNS0821 therapy, including combination bevacizumab, irinotecan, and temozolomide, referred to as "TIB." Each TIB cycle includes oral temozolomide (200 mg/m2/day) for the first 5 days, intravenous (IV) bevacizumab (10 mg/kg/dose), and IV irinotecan (125 mg/m2/dose or 340 mg/m2) on days 1 and 15 of each cycle. Patient medical history, prior treatment, therapy toxicity, response, and outcome were collected. The analysis included Kaplan-Meier estimates of 3-year overall survival (OS) and 3-year progression-free survival.

Results: Fifteen patients were treated with TIB for relapsed medulloblastoma at SCH (median age 5.81 (0.21-23.6) years, 60% male). Twelve patients completed planned therapy. Therapy was discontinued for toxicity (n = 1) and family preference (n = 1). The most common toxicities were thrombocytopenia (n = 7), neutropenia (n = 4), nausea (n = 5), vomiting (n = 5), and diarrhea (n = 3). Five patients required dose modification of one agent for toxicity. Median follow-up from TIB therapy start was 1.61 (0.47-7.66) years. Three-year OS was 48% (95% CI: 18%-74%) and 3-year event-free survival was 16% (95% CI: 1%-49%).

Conclusions: TIB was well-tolerated in pediatric patients with relapsed medulloblastoma, and outcomes were similar to those published in clinical trials. TIB therapy should be considered for patients with relapsed medulloblastoma, especially patients with limited access to care due to travel barriers.

Keywords: children; medulloblastoma; pediatric; relapse.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant conflicts of interest or disclosures related to this manuscript.

References

    1. Ostrom QT, Price M, Neff C, et al.CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol. 2023;25(12 suppl 2):iv1–iv99. - PMC - PubMed
    1. Lazow MA, Palmer JD, Fouladi M, Salloum R.. Medulloblastoma in the Modern Era: Review of contemporary trials, molecular advances, and updates in management. Neurotherapeutics. 2022;19(6):1733–1751. - PMC - PubMed
    1. Gottardo NG, Gajjar A.. Current therapy for medulloblastoma. Curr Treat Options Neurol. 2006;8(4):319–334. - PubMed
    1. Jackson K, Packer RJ.. Recent advances in pediatric medulloblastoma. Curr Neurol Neurosci Rep. 2023;23(12):841–848. - PMC - PubMed
    1. Thorarinsdottir HK, Rood B, Kamani N, et al.Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer. 2007;48(3):278–284. - PubMed

LinkOut - more resources